Bladder Cancer Weekly

October 07, 2024

Videos

Peer-to-Peer Clinical Conversations

Early Bladder Recurrence Common in UTUC Patients Post-Nephroureterectomy Despite BCG Treatment - Paul Crispen

Paul Crispen

Sam Chang host Paul Crispen to discuss his study on BCG efficacy in patients with upper tract urothelial carcinoma following nephroureterectomy.

View

SunRISe-1 Trial Advances Bladder Cancer Treatment with TAR-200 - Michiel Van der Heijden

Michiel Van der Heijden

Zach Klaassen interviews Michiel Van der Heijden about the SunRISe-1 trial, which evaluates TAR-200 with or without cetrelimab in BCG-unresponsive high-risk non-muscle-invasive bladder cancer.

View

Beyond the Abstracts

Stereotactic Body Radiation Therapy Is Beneficial for a Subgroup of Patients with Urothelial Cancer and Solitary Metastatic Disease: A Single Institution Real-World Experience - Beyond the Abstract

Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma - Beyond the Abstract

Conference Coverage

ASTRO 2024: Pembrolizumab Monotherapy Following Tri-Modality Treatment for Selected Patients with Muscle-Invasive Bladder Cancer

ASTRO 2024: Integrating Novel Therapeutics with Trimodal Therapy (TMT)

ASTRO 2024: Bladder Cancer - The Dawn or Era of More Personalized Radiotherapy

ASTRO 2024: Bladder Adjuvant RadioTherapy (BART): Acute and Late Toxicity from a Phase III Multicenter Randomized Controlled Trial

ASTRO 2024: Bladder Preservation - A Modern Choice for Patients

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Quantification of micropapillary component on transurethral resection is associated with likelihood of occult lymph node metastasis at radical cystectomy.

The genomic and transcriptomic landscape of metastastic urothelial cancer.

Survival Rates in Trimodal Therapy Versus Radiotherapy in Urothelial Carcinoma of Urinary Bladder.

Tranexamic Acid During Radical Cystectomy: A Randomized Clinical Trial.

Benefit of Whole-Pelvis Radiation for Patients With Muscle-Invasive Bladder Cancer: An Inverse Probability Treatment Weighted Analysis.

Bladder Adjuvant RadioTherapy (BART): Acute and Late Toxicity from a Phase III Multicentre Randomized Controlled Trial: Acute and late toxicity in BART RCT.

Bacillus Calmette-Guerin (BCG) Vaccine Impact on Dementia Risk in Bladder Cancer Patients: A Systematic Review and Meta-Analysis.

Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer

Gut Microbiota Influence Bladder Tumour Development

The role of radical cystectomy and lymphadenectomy in the management of bladder cancer with clinically positive lymph node involvement.

Systemic Inflammation Indexes and Risk of Immune-related Adverse Events in Patients With Metastatic Urothelial Carcinoma Treated With Immunotherapy.

Characterizing Psychological Resources and Resilience in Patients With Bladder Cancer: Associations With Frailty and Quality of Life.

Prognostic Nomogram, Demographics and Comparative Analysis of Urinary Bladder Small Cell and Large Cell Neuroendocrine Carcinoma.

Clinical Implementation of Urinary Biomarkers for Surveillance of Non-muscle-invasive Bladder Cancer (NMIBC): Considerations from the European Association of Urology NMIBC Guideline Panel.

Evaluating the Survival Benefits of Perioperative Chemotherapy in Frail and Morbid Muscle-Invasive Bladder Cancer Patients.

Muscle-Invasive Bladder Cancer in Non-Curative Patients: A Study on Survival and Palliative Care Needs

Adjuvant radiation therapy for locally advanced bladder cancer: A safe and promising emerging treatment option

Does the Extent of Transurethral Resection after Radiation Therapy Impact Survival Outcomes in Muscle-Invasive Bladder Cancer - Expert Commentary

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Bladder Cancer Weekly

Bladder Cancer

Login